Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly’s Psoriasis Drug Taltz Set For Second Quarter Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Ixekizumab had a smooth FDA approval, with no advisory committee needed for the second member of the IL-17 inhibitor class.

You may also be interested in...



Lilly Management Reorg Brings In Shaw To Oversee Bio-Medicines

Shaw is the former US President of rival Novartis and a rising figure in big pharma. She will take over the role previously held by Ricks, who became CEO Jan. 1. Conterno will assume President USA role.

Valeant’s Brodalumab Delayed By FDA As REMS Is Negotiated

FDA notified the company the US review goal date for the psoriasis pill has been extended three months from Nov. 16 to Feb. 16.

Novartis Pulling Out All The Stops To Amp Up Entresto Sales

The company has set a sales goal of $200m for Entresto in 2016, not an enormous amount for a drug that is expected to eventually be a multi-billion dollar seller, but ambitious given its slow first quarter start.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel